Traditional Chinese medicines for non-small cell lung cancer: Therapies and mechanisms

Kong, Fanming; Wang, Chaoran; Zhao, Linlin; Liao, Dongying; Wang, Xiaoqun; Sun, Binxu; Yang, Peiying; Jia, Yingjie

doi:10.1016/j.chmed.2023.05.004

Cited by 6 publications

(1 citation statement)

References 70 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirdly, all signal detection results merely indicate statistical correlations in which adverse events occurred and could not represent all cases in which capmatinib was used, necessitating further evaluation and research to ascertain the presence of a genuine causal relationship. Fourthly, several Traditional Chinese medicines have demonstrated effectiveness in treating NSCLC 30 , 31 . It is necessary to conduct further research to explore the effect of Traditional Chinese medicines combined with camatinib in alleviating adverse reactions.…”

Section: Discussionmentioning

confidence: 99%

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib

Qi,

Li,

Lin

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Capmatinib is a potent selective mesenchymal-epithelial transition inhibitor approved in 2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is very limited, this study evaluated capmatinib-induced adverse events through data mining of the FDA Adverse Event Reporting System database. Four disproportionality analysis methods were employed to quantify the signals of capmatinib-related adverse events. The difference in capmatinib-associated adverse event signals was further investigated with respect to sex, age, weight, dose, onset time, continent, and concomitant drug. A total of 1518 reports and 4278 adverse events induced by capmatinib were identified. New significant adverse event signals emerged, such as dysphagia, dehydration, deafness, vocal cord paralysis, muscle disorder, and oesophageal stenosis. Notably, higher risk of alanine aminotransferase and aspartate aminotransferase increases were observed in females, especially when capmatinib was combined with immune checkpoint inhibitors. Compared with Europeans and Asians, Americans were more likely to experience peripheral swelling, especially in people > 65 years of age. Renal impairment and increased blood creatinine were more likely to occur with single doses above 400 mg and in Asians. This study improves the understanding of safety profile of capmatinib.

show abstract

Section: Discussionmentioning

confidence: 99%

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib

Qi,

Li,

Lin

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

Sinensetin inhibits the movement ability and tumor immune microenvironment of non‐small cell lung cancer through the inactivation of AKT/β‐catenin axis

Shi,

Shen,

Liu

et al. 2024

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Although current treatment strategies have improved clinical outcomes of non‐small cell lung cancer (NSCLC) patients, side effect and prognosis remain a hindrance. Thus, safer and more effective therapeutical drugs are needed for NSCLC. Sinensetin (Sin) is a flavonoid from citrus fruits, which exhibits antitumor effect on diverse cancers. However, the effect and mechanism of Sin on NSCLC remain unknown. In this study, NSCLC cell lines, and tumor‐bearing mice were treated with Sin. The effect and mechanism of Sin were addressed using cell counting kit‐8, transwell, enzyme‐linked immunosorbent assay, hematoxylin and eosin, immunohistochemistry, and western blot analysis assays in both cell and animal models. Sin reduced the cell viability of A549 and H1299, with the IC50 of 81.46 µM and 93.15 µM, respectively. Sin decreased invaded cell numbers, the expression of N‐cadherin and vascular endothelial growth factor A (VEGFA), while increased the E‐cadherin level, the cytotoxicity of CD8+ T cells, and the concentration of interferon‐γ (IFN‐γ), interleukin‐2 (IL‐2), and tumor necrosis factor‐α (TNF‐α) in NSCLC cells. Mechanistically, Sin declined the expression of protein kinase B (AKT)/β‐catenin pathway, which was restored with the application of SC79, an activator of AKT. The inhibitory role of Sin in NSCLC cell proliferation, invasion, epithelial‐mesenchymal transition (EMT) and immune escape was reversed by the management of SC79. In vivo, Sin reduced tumor size and weight, and the expression of N‐cadherin, VEGFA, and AKT/β‐catenin pathway, but enhanced the level of E‐cadherin and IFN‐γ. Taken together, Sin suppressed cell growth, invasion, EMT and immune escape via AKT/β‐catenin pathway in NSCLC.

show abstract

Enhancing Chemoimmunotherapy for Colorectal Cancer with Paclitaxel and Alantolactone via CD44-Targeted Nanoparticles: A STAT3 Signaling Pathway Modulation Approach

Wu,

An,

et al. 2024

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Traditional Chinese medicines for non-small cell lung cancer: Therapies and mechanisms

Cited by 6 publications

References 70 publications

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib

Sinensetin inhibits the movement ability and tumor immune microenvironment of non‐small cell lung cancer through the inactivation of AKT/β‐catenin axis

Enhancing Chemoimmunotherapy for Colorectal Cancer with Paclitaxel and Alantolactone via CD44-Targeted Nanoparticles: A STAT3 Signaling Pathway Modulation Approach

Contact Info

Product

Resources

About